Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma
暂无分享,去创建一个
E. Castellón | H. Contreras | C. Sánchez | M. Clementi | D. Benitez | C. Huidobro | Catherine Sánchez | Marisa Clementi | Dixan A. Benitez
[1] G. Nolan,et al. Neurotrophin dependence domain , 2000, Journal of Molecular Neuroscience.
[2] S. Byers,et al. The p75NTR mediates a bifurcated signal transduction cascade through the NF kappa B and JNK pathways to inhibit cell survival. , 2005, Experimental cell research.
[3] L. Sáenz,et al. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. , 2005, International journal of andrology.
[4] Fatima S. Khwaja,et al. Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. , 2004, Anticancer research.
[5] X. Montano,et al. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer , 2004, FEBS letters.
[6] Javier Hernandez,et al. Diagnosis and treatment of prostate cancer. , 2004, The Medical clinics of North America.
[7] E. Small,et al. Advances in prostate cancer. , 1999, Current opinion in oncology.
[8] S. Hayward,et al. Role of the stromal microenvironment in carcinogenesis of the prostate , 2003, International journal of cancer.
[9] M. Motta,et al. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. , 2003, Endocrine-related cancer.
[10] D. Bredesen,et al. Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). , 2003, Cytokine & growth factor reviews.
[11] Fatima S. Khwaja,et al. The p75NTR tumor suppressor induces caspase‐mediated apoptosis in bladder tumor cells , 2003, International journal of cancer.
[12] Fatima S. Khwaja,et al. Inhibition of cell‐cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor , 2003, Molecular carcinogenesis.
[13] C. McArdle,et al. Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. , 2003, The Journal of endocrinology.
[14] D. Djakiew,et al. Neurotrophin receptor p75NTR suppresses growth and nerve growth factor‐mediated metastasis of human prostate cancer cells , 2002 .
[15] D. Djakiew,et al. Molecular characterization of the loss of p75NTR expression in human prostate tumor cells , 2001, Molecular carcinogenesis.
[16] N. Singh,et al. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. , 2000, Mutation research.
[17] A. Weeraratna,et al. Rational basis for Trk inhibition therapy for prostate cancer , 2000, The Prostate.
[18] L. Frati,et al. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. , 2000, Journal of andrology.
[19] D. Bostwick,et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. , 2000, The Journal of urology.
[20] C. Vancheri,et al. Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. , 2000, Molecular endocrinology.
[21] Y. Wong,et al. Growth factors and epithelial-stromal interactions in prostate cancer development. , 2000, International review of cytology.
[22] M. Chao,et al. Neurotrophin receptor structure and interactions. , 2000, Pharmaceutica Acta Helvetiae.
[23] H. Kong,et al. A comparison of the cytoplasmic domains of the Fas receptor and the p75 neurotrophin receptor , 1999, Cell Death and Differentiation.
[24] Guate,et al. Expression of p75LNGFR and Trk neurotrophin receptors in normal and neoplastic human prostate , 1999, BJU international.
[25] S. Dirnhofer,et al. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors , 1999, Experimental Gerontology.
[26] G. Sica,et al. Effect of Leuprorelin Acetate on Cell Growth and Prostate-Specific Antigen Gene Expression in Human Prostatic Cancer Cells , 1998, European Urology.
[27] D. Djakiew,et al. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor–induced cell growth by activation of programmed cell death , 1998, Molecular carcinogenesis.
[28] A. Schally,et al. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. , 1998, International journal of oncology.
[29] D. Newling,et al. Neurotrophic factors in prostate and prostatic cancer , 1998, Prostate Cancer and Prostatic Diseases.
[30] D. Djakiew,et al. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate , 1997, Molecular and Cellular Endocrinology.
[31] D. Djakiew,et al. Loss of low‐affinity nerve growth factor receptor during malignant transformation of the human prostate , 1997, The Prostate.
[32] M. Motta,et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. , 1996, The Journal of clinical endocrinology and metabolism.
[33] B. Hempstead,et al. p75 and Trk: A two-receptor system , 1995, Trends in Neurosciences.
[34] D. Kaplan,et al. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. , 1995, Endocrinology.
[35] M. Motta,et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. , 1994, Cancer research.
[36] A. Schally,et al. Responses to the antagonistic analog of LH‐RH (SB‐75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer , 1994, The Prostate.
[37] D. Djakiew,et al. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. , 1992, Cancer research.
[38] M. Motta,et al. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. , 1992, The Journal of clinical endocrinology and metabolism.
[39] D. Djakiew,et al. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. , 1992, The Journal of urology.
[40] J. Isaacs,et al. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. , 1992, Cancer research.
[41] G. Wilding. The importance of steroid hormones in prostate cancer. , 1992, Cancer surveys.
[42] M. Gleave,et al. Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.
[43] A. Schally,et al. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. , 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[44] Martin R. Schneider,et al. Effect of the new potent LHRH antagonist antide , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[45] A. Schally,et al. Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia , 1989, The Prostate.
[46] J. Minna,et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. , 1987, Cancer research.
[47] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.